Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

Fiammetta Vanolia Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy;b Piazzale Aldo Moro 5, Department of Human Neurosciences Sapienza University of Rome, Rome, ItalyCorrespondence[email protected]

https://orcid.org/0000-0002-9081-6462 View further author information

Renato Mantegazzaa Neuroimmunology and Neuromuscular Disease Department, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy

https://orcid.org/0000-0002-9810-5737 View further author information

References

Francesc C, Sander HW, Fernández S. Intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis. Expert Opin Pharmacother. 2023;24. just-accepted. DOI:10.1080/14656566.2023.2192867
Google Scholar
Vanoli F, Mantegazza R. What are the pharmacotherapeutic con- siderations for the treatment of myasthenia gravis? Expert Opin Pharmacother. 2022;23:1471–1474.
PubMed Web of Science ®Google Scholar
Zinman L, Ng E, Bril V. IV immunoglobulin in patients with myasthenia gravis: a randomized controlled trial. Neurology. 2007;68:837–841.
PubMed Web of Science ®Google Scholar
Karelis G, Balasa R, De Bleecker JL, et al. A Phase 3 multicenter, prospective, open-label efficacy and safety study of immune glo- bulin (Human) 10% caprylate/chromatography purified in patients with myasthenia gravis exacerbations. Eur Neurol. 2019;81:223–230.
PubMed Web of Science ®Google Scholar
Barth D, Nabavi Nouri M, Ng E, et al. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology. 2011;76:2017–2023.
PubMed Web of Science ®Google Scholar
Murai H. J apanese clinical guidelines for myasthenia gravis: putting into practice. Clin Exp Immunol. 2015;6(1):21–31.
Google Scholar

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Reply to: intravenous immunoglobulin (Gamunex® 10%) is licensed for the treatment of severe acute exacerbations of myasthenia gravis

References

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date